45-minutes. No compromises.

Vancomycin Resistant Enterococcus (VRE) is a critical pathogen among high risk patients. Previous testing methodologies are time consuming and often require unnecessary isolation. Xpert^® vanA empowers clinicians to make critical decisions at time of patient admission, thereby improving the quality of patient care and reducing cost.

Runs On: GeneXpert^® System

The Need

According to the Centers for Disease Control and Prevention (CDC), Enterococci cause about 1 of every 8 hospital infections with 30% of those infections, caused by Vancomycin-Resistant Enterococci (VRE). However, VRE can be even more prevalent in high risk groups, such as immunocompromized and ICU patients.
The human and financial impact of VRE is high:

• Attributable mortality: 10%
• Extended length of stay: 6.2 days
• Incremental cost: $12,800

The Solution

The CDC and SHEA have both published guidelines on how to reduce or eliminate healthcare associated infections. As a part of a quality infection control program, Cepheid’s Xpert vanA provides:

• Immediate detection of the vanA gene most closely associated with VRE colonization
• Superior NPV required in a surveillance test
• Easy-to-use test with less than 2 minutes hands-on-time